Molecular allergen profiling in horses by microarray reveals Fag e 2 from buckwheat as a frequent sensitizer. by Einhorn, L et al.
OR I G I N A L A R T I C L E
Experimental Allergy and Immunology
Molecular allergen profiling in horses by microarray reveals
Fag e 2 from buckwheat as a frequent sensitizer
L. Einhorn1,2 | G. Hofstetter1 | S. Brandt3 | E. K. Hainisch3 | I. Fukuda4 |
K. Kusano4 | A. Scheynius5 | I. Mittermann2 | Y. Resch-Marat2 |
S. Vrtala2 | R. Valenta2 | E. Marti6 | C. Rhyner7 | R. Crameri7 | R. Satoh8 |
R. Teshima9 | A. Tanaka10 | H. Sato11 | H. Matsuda11 | I. Pali-Sch€oll1,2 |
E. Jensen-Jarolim1,2,12
1The interuniversity Messerli Research Institute, University of Veterinary Medicine Vienna, Medical University Vienna and University Vienna, Vienna, Austria
2Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
3Research Group Oncology, Equine Clinic, University of Veterinary Medicine Vienna, Vienna, Austria
4Racehorse Hospital, Miho Training Center, Japan Racing Association, Mikoma, Japan
5Science for Life Laboratory, Department of Clinical Science and Education, Karolinska Institutet, and Sachs’ Children and Youth Hospital, S€odersjukhuset,
Stockholm, Sweden
6Department of Clinical Research and Veterinary Public Health, Vetsuisse Faculty, University of Bern, Bern, Switzerland
7Swiss Institute for Allergy and Asthma Research (SIAF), Davos, Switzerland
8Division of Food Function Research, Food Research Institute, National Agriculture and Food Research Organization, Tsukuba, Japan
9National Institute of Health Sciences, Tokyo, Japan
10Laboratory of Comparative Animal Medicine, Division of Animal Life Science, Tokyo University of Agriculture and Technology, Fuchu, Japan
11Laboratory of Veterinary Molecular Pathology and Therapeutics, Division of Animal Life Science, Tokyo University of Agriculture and Technology, Fuchu,
Japan
12AllergyCare, Allergy Diagnosis and Study Center, Vienna, Austria
Correspondence
Prof. Erika Jensen-Jarolim, Institute of
Pathophysiology and Allergy Research,
Center of Pathophysiology, Infectiology &
Immunology, Vienna, Austria.
Email: erika.jensen-jarolim@meduniwien.ac.at
Funding information
Austrian Science Fund, Grant/Award
Numbers: MCCA DK W1248-B30, P26728-
B20, SFB F4605, SFB F4606-B28
Edited by: Hans-Uwe Simon
Abstract
Background: Companion animals are also affected by IgE-mediated allergies, but
the eliciting molecules are largely unknown. We aimed at refining an allergen
microarray to explore sensitization in horses and compare it to the human IgE reac-
tivity profiles.
Methods: Custom-designed allergen microarray was produced on the basis of the
ImmunoCAP ISAC technology containing 131 allergens. Sera from 51 horses
derived from Europe or Japan were tested for specific IgE reactivity. The included
horse patients were diagnosed for eczema due to insect bite hypersensitivity,
Abbreviations: BSA, bovine serum albumin; CAP, caponized; Cy3, cyanine 3 fluorophore; HDM, house dust mite; H, hour; HRP, horse radish peroxidase; ISAC131, ISAC, custom-designed
with 131 allergen molecules; ISAC, immuno-solid-phase allergen chip; ISU-E, ISAC standardized units for IgE; ISU, ISAC standardized units; Min, minute; RAO, recurrent airway obstruction;
rFag e 2, recombinant Fag e 2; RT, room temperature; SDS-PAGE, sodium dodecyl sulphate–polyacrylamide gel electrophoresis; TBST, Tris-buffered saline with Tween 20.
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chronic coughing, recurrent airway obstruction and urticaria or were clinically
asymptomatic.
Results: Horses showed individual IgE-binding patterns irrespective of their health
status, indicating sensitization. In contrast to European and Japanese human sensiti-
zation patterns, frequently recognized allergens were Aln g 1 from alder and Cyn d
1 from Bermuda grass, likely due to specific respiratory exposure around paddocks
and near the ground. The most prevalent allergen for 72.5% of the tested horses
(37/51) was the 2S-albumin Fag e 2 from buckwheat, which recently gained impor-
tance not only in human but also in horse diet.
Conclusion: In line with the One Health concept, covering human health, animal
health and environmental health, allergen microarrays provide novel information on
the allergen sensitization patterns of the companion animals around us, which may
form a basis for allergen-specific preventive and therapeutic concepts.
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1 | INTRODUCTION
Allergies also affect domestic animals, such as dogs, cats and
horses.1 The same allergen sources as in human allergy may be rele-
vant for animals, such as pollen2 or food allergens.3 The importance
of comparing human and animal allergic diseases and causative aller-
gens has recently been acknowledged by the establishment of an
interest group for Comparative and Veterinary Allergology in the
European Academy of Allergy and Clinical Immunology (EAACI). In
fact, comparative allergology ideally fits into the “One Health Con-
cept,” which relies on three main pillars: human health, animal health
and environmental health.4
In horses, allergen hypersensitivity5 leads to cutaneous symp-
toms, that is eczema6 or urticaria,7 and/or to respiratory symptoms
in form of chronic coughing or recurrent airway obstruction
(RAO).8,9 In equine RAO, the exposure to allergens from hay and
straw dust and induced symptoms are associated with increased
plasma histamine levels10; however, at least in case of the fungus
Aspergillus, in vitro IgE diagnosis and intradermal IgE levels do not
support IgE-mediated mechanisms.11 In general, involvement of IgE-
mediated mechanisms in RAO is still controversial.
The phenomenon of insect bite hypersensitivity (IBH) which
especially occurs in Icelandic ponies and leads to “summer eczema”
with severe pruritus, alopecia and crusting12 is the best investigated
equine atopic disease thus far.13 IBH can also be associated with
bronchial hyper-reactivity14 and hence mirrors the human atopic
syndrome characterized by cutaneous and respiratory symptoms.15
Interestingly, environmental allergen sources such as house dust
mites (HDM), moulds16 and pollen2,17 likewise elicit allergic symp-
toms in horses.
In addition, several food allergen sources have been described
being potentially relevant for horses, including oats, wheat or corn.18
A major preventive and therapeutic strategy is to avoid feeding
potential allergens. Hence, identification of such allergens is absolutely
crucial.19
Diagnosis of allergic conditions and desensitization therapy in
domestic animals is today performed with allergen extracts.17,20
Intradermal challenge with extracts is a well-established test proce-
dure in equine allergology.21 However, some studies have yielded
conflicting results, that is either better diagnostic accuracy than con-
ventional serological tests22 or weaker reproducibility.23 In this con-
text, sensitive assessment of horse serum for the presence of
allergen-specific IgE may represent a valuable diagnostic option, all
the more as blood can be collected on-site without sedation.1,24-27
In recent years, innovative methods for reliable allergy diagnosis
have been developed. In contrast to crude allergen extracts, molecu-
lar allergy diagnosis is based on single natural or recombinant aller-
gen molecules. Molecular allergy diagnosis has entered clinical
practice in humans,28 allowing either approaches “from clinics to
molecules” or “from molecules to clinics”.29 It is debated whether it
might replace skin testing screenings in the future,30 or not.31
In particular, the immuno-solid-phase allergen chip (ISAC) has
revolutionized human allergy diagnosis. The first ISAC microarray
has enabled serum IgE testing on 94 allergens32,33; the next-genera-
tion microarray ISAC112 extended to 112 molecules is applied in
today0s daily allergy diagnosis.28 Recently, an experimental ISAC for-
mat comprising 176 allergen molecules has been used in the Euro-
pean Union-funded research project MeDALL to determine IgE
sensitizations in birth cohorts.34 Allergen chip-based diagnostic tools
allow a risk evaluation for the grade of allergic reaction to be
expected by providing individual IgE sensitization profiles. For
example, in food allergy, IgE antibodies specific for very stable pro-
teins such as 2S-albumins or to lipid transfer proteins (LTPs) indi-
cate a higher risk for systemic reactions in a sensitized individuals.
In contrast, IgE antibodies to unstable pathogenesis-related (PR)
molecules of the PR10 family imply a lower risk. For all these
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reasons, it is unfortunate that component-resolved diagnosis has
not yet reached veterinary allergy diagnosis. This is one reason why
today there is still a knowledge gap regarding allergen components
relevant in the animals.35
To this aim, we expanded an allergen chip for IgE serology in ani-
mals adding 19 more molecules of potential relevance in veterinary
allergy diagnosis (Table S1). We considered proteins from the follow-
ing allergen sources potentially important: from other animals (albu-
mins from rat, guinea pig and rabbit; lipocalin from mouse; alpha-
Gal; from human (uteroglobin, IgG, profilin and Hom s 236), from the
commensal yeast Malassezia associated with a number of different
skin disorders such as atopic eczema,37,38 from midges,39,40 relevant
via skin41-43 and from plant food.44
In a pilot study, using sera from clinically well-characterized aller-
gic horses with various symptoms and horses without clinical allergy
(Table 1), we established IgE testing on ISAC131.
2 | MATERIALS AND METHODS
2.1 | Horse patients
Sera from 41 horses suffering from diverse allergic symptoms and
10 horses without apparent clinical symptoms that were included
(28 female, 12 entire males, 11 geldings), median age 12 years (range
2-26 years), from Austria, Switzerland, Germany, Iceland and Japan
were analysed (Table 1).
Sera were used retrospectively from other studies which were
approved by the Ethics Committee of the University of Veterinary
Medicine Vienna (GZ 68.205/0236-II/3b/2011 und 68.205/0151-II/
3b/2013), by the Animal Experimental Committee of the Canton of
Berne, Switzerland (No. BE 51/13) and by the Animal Care and Use
Committee of Japan Racing Association (#2016-9).
2.2 | Design of ImmunoCAP allergen microchip
ISAC131
In total, 131 allergen molecules (ie 112 from the commercial ISAC112
(ImmunoCAPTM ISAC, Thermo Fisher Scientific, Uppsala, Sweden),
additionally 19 allergen molecules from 9 different allergen sources)
were spotted using the ImmunoCAP ISAC technology as previously
described33, rendering ISAC131 (Table S1; Figure 1A). The spotting
concentration had been optimized in pre-experiments and ranged
between 0.1 - 0.5 mg/mL antigen; spotted allergens were verified by
specific antisera. Similarly, serum dilution strategy and detection anti-
body concentrations were optimized in pre-experiments.
All detection steps were carried out according to the manufac-
turer’s instruction, with slight modifications: Thirty lL undiluted horse
serum was incubated on ISAC131 for 2 hours, and glass slides were
then washed with ThermoFisher washing fluid. IgE detection (1 hour
at RT) was performed 1 hour with 30 lL monoclonal mouse anti-
horse IgE antibody clone 3H10 (Bio-Rad, Hercules, CA, USA) self-
labelled with Cy3 (Bio-Rad, UK), diluted 1:100 in IgE dilution buffer
(Thermo Fisher). After final washing, fluorescence was measured in
an ISAC microchip-reader (LUX-Scan-10K/A; CapitalBio Corporation,
Beijing, China) with excitation at 532 nm (green laser). As the human
IgE standard designed for IgE detection in human sera on ISAC112
could not be used, a work-around was developed with the team of
ThermoFisher, using an alternative positive signal with horse IgE on a
spotted allergen as reference and comparing all values hereto in a
semiquantitative manner. Microarray image data were analysed by
MIA (Microarray Image Analysis Software, V1.2, Thermo Fisher Scien-
tific, Uppsala, Sweden), and the ISAC standardized units (ISU) were
calculated by comparing with a calibration curve (specific IgE CTRL,
Thermo Fisher Scientific, Vienna, Austria, CTR02) (Figure S1B). ISU
values above 0.3 ISU were considered positive.
3 | RESULTS
3.1 | Characterization of Equine patients
A representative sample of 51 equine patients from different geo-
graphic areas, Iceland, central Europe (Austria, Germany, Switzerland,
Hungary) and Japan, was assembled and horses grouped according
to their clinical history (Table 1). Thirteen Icelandic horses suffered
from insect bite hypersensitivity, corresponding to “summer eczema,”
in one of them combined with coughing; 4 horses (an Icelandic
horse, a Trakehner x Furioso cross-breed, a German riding pony and
a Polish cross-breed) were diagnosed with equine asthma, most
affected by more severe and chronic recurrent airway obstruction
(RAO), except patient number 29 (3 years old) with milder inflamma-
tory airway disease (IAD)9; 10 horses (4 Icelandic horses, and one
each Trakehner, Hanoverian horse, Trotter, Shagya Arabian, German
riding pony and a Holsteiner x Oldenburger Warmblood cross-breed)
were diagnosed with coughing, most often seasonally associated, or
elicited by hay dust; all 14 Japanese Thoroughbred horses suffered
from urticaria; and finally, 10 horses without allergic symptoms (6
Icelandic horses, a Hungarian Warmblood, a Knabstrupper, a Welsh
Mountain Pony and a Pony-cross-breed), completed the panel.
3.2 | Testing for specific equine IgE by ISAC131
Serum samples of all horses were tested on ISAC131 multiplex array
(Figure S1A, B) for IgE binding to 131 allergens: 112 corresponding
to commercial ISAC112, plus 19 additional allergens (Table S1). The
additional allergens were selected due to potential impact for veteri-
nary patients35 and comprised molecular allergens from other ani-
mals (albumins, lipocalins and alpha-Gal), human antigens,36 the
yeast associated with atopic dermatitis (Malassezia sympodialis, previ-
ously designated Malassezia furfur),37,38 biting midges (Culicoides
nubeculosus) responsible for summer eczema,12,39,40 high molecular
weight enzymatic HDM allergens,42,45,46 papain43 and one plant
allergen44 (Table S1).
Representative results of equine IgE binding on ISAC131 (Fig-
ure 1) illustrate that IgE-binding patterns were diverse and indicated
individually differing specific IgE profiles. To extract the most impor-
tant trends from the 6812 results (131 allergens 9 51 sera),
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TABLE 1 Characterization of equine patients
Patient no. Breed Sex Age (years) Origin Symptoms
1 Icelandic horse M 16 Iceland Switzerland eczema, summer
2 Icelandic horse F 16 Iceland Switzerland eczema, summer
3 Icelandic horse M 25 Iceland Switzerland eczema, summer
4 Icelandic horse F >20 Iceland Switzerland eczema, summer
5 Icelandic horse F 20 Iceland Switzerland eczema, summer
6 Icelandic horse F 22 Iceland Switzerland eczema, summer
7 Icelandic horse F 22 Iceland Switzerland eczema, summer
8 Icelandic horse F 23 Iceland Switzerland eczema, summer
10 Icelandic horse F 14 Iceland Switzerland eczema, summer
12 Icelandic horse F 7 Iceland Switzerland eczema, summer
14 Icelandic horse F 7 Iceland Austria eczema
15 Icelandic horse F 11 Iceland Austria eczema
18 Icelandic horse M 11 Iceland Austria eczema, coughing
13 Icelandic horse F 12 Iceland Austria RAOa
21 Trakehner x Furioso M (cap.)b 9 Austria RAO
25 German riding pony M (cap.) 20 Austria RAO
37 Polish half breed M (cap.) 14 Poland RAO
19 Trakehner M (cap.) 12 Austria coughing
20 Hanoverian horse F 17 Germany coughing, seasonal
22 Trotter F 12 Austria coughing, seasonal
24 Shagya Arabian F 17 Hungary coughing, seasonal
26 German riding pony F 13 Austria coughing, seasonal
29 Holsteiner x Oldenburger M (cap.) 3 Austria coughing, seasonal
33 Icelandic horse F 21 Austria coughing, seasonal
36 Icelandic horse M (cap.) 22 Iceland coughing, seasonal
23 Icelandic horse F 15 Austria coughing, hay dust
35 Icelandic horse M (cap.) 22 Austria coughing, hay dust
38 Thoroughbred M 3 Japan urticaria
39 Thoroughbred F 5 Japan urticaria
40 Thoroughbred M 4 Japan urticaria
41 Thoroughbred M 3 Japan urticaria
42 Thoroughbred F 3 Japan urticaria
43 Thoroughbred M 4 Japan urticaria
44 Thoroughbred M 3 Japan urticaria
45 Thoroughbred M 6 Japan urticaria
46 Thoroughbred F 3 Japan urticaria
47 Thoroughbred F 5 Japan urticaria
48 Thoroughbred M (cap.) 4 Japan urticaria
49 Thoroughbred M 3 Japan urticaria
50 Thoroughbred F 3 Japan urticaria
51 Thoroughbred F 2 Japan urticaria
9 Icelandic horse M 23 Germany without
11 Icelandic horse M 15 Germany without
16 Icelandic horse F 6 Austria without
17 Icelandic horse F 26 Austria without
32 Icelandic horse F 20 Austria without
(Continues)
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allergens were grouped (Figure 2), into percutaneous and respiratory
sensitizers including yeast, HDM and insect-derived molecules (Fig-
ure 2A), human and animal allergens (Figure 2B), pollen allergens
(Figure 2C) and food allergens (Figure 2D). Only results accounting
for over 10% of the cohort will be discussed in depth in the light of
clinical symptoms. In the allergen group A (Figure 2A), 6 horses
TABLE 1 (Continued)
Patient no. Breed Sex Age (years) Origin Symptoms
34 Icelandic horse F 24 Austria without
27 Hungarian Warmblood M (cap.) 8 Hungary without
28 Knabstrupper F 3 Germany without
30 Welsh Mountain Pony M (cap.) 18 Austria without
31 Pony x Shagya Arabian M (cap.) 6 Austria without
aRAO: recurrent airway obstruction.
bcap.: caponized.
F IGURE 1 Typical laser scanning pictures resulting from testing for equine IgE on custom-designed ISAC131. Different IgE profiles in
ISAC131 are shown exemplarily for equine patients (A) no. 05; (B) no. 15; (C) no. 21; (D) no. 49 without any specific IgE to the tested
allergens (clinical details in Table 1). The signal intensity corresponding to the level of specific IgE binding to 131 allergens spotted in triplicates
is indicated in false colours shown in the scale below: blue, weak reactivity; green to yellow, moderate; red to white, strong IgE binding.
Triplicate spots at upper left, upper right, lower left and lower right corners are spotted with calibration standards. Spotting map in Figure S1,
additional allergens on ISAC131 in Table S1
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reacted specifically to fungal Alt a 1, to worm Ani s 1, cockroach Bla
g 1 (mean signal intensity 1.63 ISU), earth wasp venom Pol d 5
(mean 1.52 ISU), and M. sympodialis Mal s 10 and Mal s 12 allergens.
IgE-binding intensities were highest in the 5 horse sera reacting to
bee Api m 1 (mean 4.9 ISU).
In group B with human and animal antigens (Figure 2B), 12
horses reacted to canine Can f 3 allergen and 12 showed IgE autore-
activity to equine Equ c 1.
Among pollen allergens (Figure 2C), 18 horses reacted to alder
Aln g 1 (mean 2.00 ISU), 14 to Bermuda grass Cyn d 1 (mean
3.82 ISU), 6 to timothy grass Phl p 4 (mean 1.69 ISU) and 6 to weed
pollen Che a 1 (mean 1.71 ISU). In respect to food allergens (Fig-
ure 2D), 5 horses reacted to apple Mal d 1 (mean 3.24 ISU) from
the PR10 family, 7 to Pen m 2 (mean 1.21 ISU) and 11 to Pen m 4
(mean 1.75 ISU) from shrimp. In total, 37 horses reacted via IgE to
Fag e 2 from buckwheat (mean 5.61 ISU), among them also 7 horses
from the group without symptoms.
Overall, the most abundant IgE sensitizations were seen to Fag e
2 > Cyn d 1 > Aln g 1, but we were not able to find correlations
between sensitization patterns in the different clinical cohorts
(Table 1).
All clinical groups show a comparable prevalence of IgE reactivity
to buckwheat allergen Fag e 2, between 62% of sera from eczema,
up to 100% in RAO patients (Table 2). Highest IgE-binding intensi-
ties above 10 ISU were observed in 1 eczema, 2 coughing and 1
urticaria patients (Figure 3). The specificity of equine IgE binding to
buckwheat and its 2S-albumin Fag e 2 was confirmed by IgE inhibi-
tion experiments in immunoblotting (Data S1 and Figure S2).
4 | DISCUSSION
Little is known about possible allergen sources for horses and espe-
cially about the responsible allergen molecules,35 including food
allergy,3 except in summer eczema, where IgE to Culicoides allergens
play an important role.40 While intradermal tests with crude Culi-
coides whole body often results in positive intradermal test reaction
in clinically healthy horses, the use of recombinant Culicoides aller-
gens allows a much more specific diagnosis of summer eczema,47 in
clinically healthy, but sensitized horses.48
We designed the ISAC131 multiplex microarray and tested the
IgE binding to 131 allergens using sera from 51 horses from differ-
ent breeds and different countries of origin (Table 1). Equine total
serum IgE levels are approximately 3 logs higher than in humans and
did previously not discriminate allergic from healthy horses.49,50 We
also found specific IgE in the group of horses without allergic symp-
toms, which we interpret as clinically inapparent sensitizations.49
The higher IgE levels in serum of horses could have caused high
background levels in ISAC131 which in three cases impeded evalua-
tion. Furthermore, especially high IgG concentrations and their possi-
ble cross-binding to the allergen,51 or competition among the
multiplexed allergens for such cross-reacting IgE could also influence
the signal quality, especially at lower IgE levels.52
In general, the ISAC131 results (Figures 2 and 3) appropriately
reflected the known susceptibility of horses to tree and grass pol-
len.2,5 Interestingly, the major alder pollen allergen Aln g 1, but not
Bet v 1 from birch pollen, was identified as a major respiratory sensi-
tizer in 18 cases. Both pollen major allergens from the botanic spe-
cies Fagales belong to the PR-10 family, a protein family with innate
immune function in plants.53 They are able to ignite Th2 immune
responses in humans and animals by their ligand-binding capacity.54
PR-10 molecules are highly cross-reactive and can sensitize human
atopic individuals; in humans, this is usually dominated by IgE
responses to the birch major allergen Bet v 1,55 at least in Middle
and Northern Europe. We speculate that possibly around paddocks
and often associated ponds, alders may be most prominent and,
therefore, represent the primary sensitizing allergen source. This the-
ory is in conflict with a recent report that for human allergics Bet v 1
is the leading allergen also in the birch-free Mediterranean area.56 In 2
of the 4 horses reacting via IgE to PR10 allergen Mal d 1 from apple,
co-sensitization to Aln g 1 could be found. To this end, it has not been
shown that horses may develop oral allergy syndrome, which in
humans is a common clinical problem due to sensitization to PR-10
allergens, also sporadically reported to occur in companion animals
other than horses.2
The second most abundant sensitization was found to Bermuda
grass allergen Cyn d 1 in 14 of the 51 horses investigated. As in the
case of tree pollen, a great degree of IgE cross-reactivity is elicited by
grass pollen, with group 1 and group 5 pollen allergens being most
important in humans. Cyn d 1 belongs to group 1 grass pollen aller-
gens, but no cross-reactivity was observed with Phl p 1 from timothy
grass. This could be due to grass seeding strategies on paddocks,
which is a hotly debated topic among horse owners. Natural (n) Cyn d
1, nPhl p 4, nApi g 5, nCup a 1 and MUXF3 on ISAC131, expresses
cross-reactive carbohydrate determinants (CCDs) which principally
could lead to nonspecific IgE binding.57 However, only in one horse
positive for Cyn d 1, simultaneous IgE reactivity could be detected to
Phl p 4 and/or Phl p 1. We consider thus anti-Cyn d 1 IgE to be speci-
fic and non-CCD dependent, at least in the cohort of our pilot study.
In addition to the animal allergens on commercial ISAC112, we
added animal and human antigens on ISAC131, however, without
revealing any significant sensitization in the investigated horse
cohorts. The most frequent sensitizer was Can f 3, serum albumin from
dog, whereas in only one horse IgE to Can f 5 was found, suggesting
exposure to a male dog.58 The IgE reactivities were in most incidences
paired with serological IgE cross-reactivity to Equ c 1, the equine lipo-
calin. We did not find IgE to cat, rabbit, rat or mouse lipocalins.
House dust mites (HDM) are abundant in households, trans-
ported by furry animals and involved in initiation and perpetuation
of atopic eczema and asthma. Their enzymatic potency is involved in
inflammation, while indispensable for specific sensitization.43
Recently, it was shown that HDM induce intelectin in epithelia,59
leading to subsequent IL-25, IL-33, and TSLP upregulation and Th2
responses. Due to the fact that dogs are frequently sensitized to
high molecular weight HDM allergens, we added Der p 15 and Der
p 18 on ISAC131,41,42 but horse IgE did neither react to the human
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F IGURE 2 Numbers of horse patients reacting with molecular allergens spotted on custom-designed ISAC131 microarray. Results are
grouped according to allergen sources: (A) percutaneous and respiratory allergens; (B) human and animal allergens; (C) pollen allergens; and (D)
food allergens. The x-axis indicates the number of horses reactive to single allergen molecules in each panel; y-axis: alphabetic codes of
allergen molecules according to the WAO/IUIS Allergen Nomenclature (http://www.allergen.org). y-axes in each panel: allergens spotted on
ISAC131, alphabetic order; x-axes: ISU-E intensities
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major HDM allergens Der p 1 or Der p 2 nor canine major allergens
Der p 15 or Der p 18 on ISAC131. Instead, 4 horses reacted to
papain, which is a functional and structural homologue of HDM
allergen Der p 1 with serine protease function. Papain may be con-
tained in shampoos and has documented percutaneous sensitization
capacity.43 Some human HDM minor allergens, such as arginine
kinase, sarcoplasmic calcium-binding protein or haemocyanin,60 are
not contained on ISAC112 or ISAC131. They are, however, cross-
reactive to homologous allergens in shrimp and insect allergy61
where they may even represent primary sensitizers.62 As we would
like to exclude shrimps as possible constituents in equine diet, we
speculate that, vice versa, IgE binding to black tiger shrimp allergens
Pen m 2 and Pen m 4 in up to 12 of the investigated horse sera
may indicate cross-sensitization to corresponding allergens in HDM,
or parasites, which are not yet contained on any ISAC.
There were a few indications of environmental exposure to Ger-
man cockroach by IgE to Bla g 1 and 5, and little evidence for fungal
exposure via IgE to Alternaria allergen Alt a 1 in 6 horses, and a
single horse reacted with IgE to Aspergillus allergen Asp f 1. Hay dust
may be contaminated with moulds, to which specific IgE (together
with specific IgG) can be formed which previously were correlated
with equine bronchitis.25 The ISU level to Alt a 1 in ISAC131 was
highest in one RAO affected horse. However, as IgE to Alt a 1 was
found in all horse groups, this does so far not allow associations to
respiratory allergic symptoms.
Only sporadic sensitizations to Mala s 1, Mal s 6, 10 and 1237
were found. These allergens are characterized from M. sympodialis a
lipid-dependent yeast, part of our normal skin microbial flora, but
also associated with several common skin disorders such as atopic
eczema/dermatitis,38,63,64 and may be associated with food allergy.65
Malassezia has so far been detected on the skin of healthy horses.66
We failed to establish the IgE-microarray testing for Culicoides
allergens Cul n 1 and Cul n 2,39,40 even in sera from the Icelandic
horses suffering from summer eczema, which were previously tested
positive for IgE to Cul n 1 and 2 in immunoblot. This may be
explained by a methodological failure resulting in insufficient spot-
ting of Cul n 1 and 2 to the microchip glass surface.
The most significant finding, however, was the high prevalence of
IgE to Fag e 2 from buckwheat in 37 of 51 tested horses from all
groups, including eczema, respiratory symptoms, urticaria and non-
symptomatic. Considering that sensitization usually correlates with
exposure, the high sensitization rate is plausible. Buckwheat predomi-
nantly grows in Middle Europe and Asia (https://commons.wikimedia.
org/w/index.php?curid=25570098), exactly from where our horse
patients originate. The buckwheat plant (Fagopyrum esculentum)
belongs to the mustard family and may elicit phototoxic reactions.67
Buckwheat plants are cultivated in main regions of Europe, Asia and
North America, and its grain-like seeds are processed to noodles, bak-
ery products and teas,68 especially in the Asian cuisine. While in Eur-
ope earlier used by poor people or in “rainy days,” there is a revival of
buckwheat as alternative protein source in “healthy” and vegan diets
today.69,70 It may contribute to the control of cholesterol levels in
TABLE 2 Specific IgE to the buckwheat allergen Fag e 2 on
ISAC131 in horses grouped by allergic symptoms
Allergic symp-
tom group
IgE to Fag e 2 in
ISAC131 relative
percentage
ISU-Ea to Fag e 2 in ISAC131
mean -STDEV
Eczema
(n = 13)
61.5% (8/13) 5.5  3.8
RAOb (n = 4) 100% (4/4) 3.4  1.5
Coughing
(n = 10)
45.5% (7/11) 8.1  7.1
Urticaria
(n = 14)
81.4% (11/14) 4.2  4.7
None (n = 10) 70% (8/10) 4.3  2.8
aISU-E, ISAC standardized units for IgE determination, cut-off 0,3
bRAO, recurrent airway obstruction.
F IGURE 3 Intensities of specific IgE of single horses to the buckwheat allergen Fag e 2 in ISAC131. X-axis: horses were grouped according
to symptoms (Summer eczema, coughing, RAO, urticaria or without/symptoms) as described in Table 2. Y-axis: levels of IgE reactivities to Fag e
2 given in ISAC standardized units (ISU-E), values <0.3 ISU were interpreted as negative (indicated by the horizontal line). Results are presented
in different colours depending on IgE-binding intensity: 0.3-0.9 ISU-E, yellow (weak); 1-14.9 ISU-E, orange (moderate); >15, ISU-E red (strong)
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animal studies,71 hypertension and diabetes,72,73 and tumour
growth.74 Interestingly, Buckwheat is a constituent of some “horse
mueslis,” or horse crackers. Unfortunately it contains Fag e 2, which
belongs to the 2S-abumin family,75 pepsin-resistant food allergens76
with the capacity to exacerbate atopic dermatitis, elicit urticaria,
angioedema and in severe cases anaphylaxis in human patients.77-79
Few studies describe human buckwheat allergy in Asia,80,81 Italy,82,83
or Britain84. This is the first report identifying IgE to Fag e 2 in equine
sera, using ISAC131. We could confirm the specificity of anti-Fag e 2
IgE binding to buckwheat in immunoblotting inhibition experiments.
This indicates that horses may be sensitized to buckwheat, which
recently has gained interest as a dietary allergen relevant for human
patients78,81 in whom buckwheat has been associated with anaphylac-
tic reactions.81 However, it remains to be investigated by the veteri-
nary discipline whether Fag e 2 indeed is responsible for any of the
clinical allergic symptoms in horses.
In conclusion, we report here that IgE testing using a multiplex
ISAC131 test rendered novel information of IgE profiles in a repre-
sentative group of 51 horses from Europe and Japan. Even though
the IgE detection to some allergens, especially Culicoides, needs to
be improved, based on our study, testing with ISAC or other allergen
microarrays could be considered as a new diagnostic opportunity for
horse patients with suspected allergen sensitization and could help
to develop preventive, avoidance and therapy strategies.
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